State of Wyoming’s Puma Biotechnology PBYI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$323K Sell
39,833
-35,975
-47% -$263K 0.03% 667
2026
Q1
$484K Buy
75,808
+22,653
+43% +$146K 0.06% 335
2025
Q4
$316K Buy
53,155
+40,418
+317% +$215K 0.03% 683
2025
Q3
$67.6K Buy
+12,737
New +$54K 0.01% 1435
2025
Q1
Sell
-20,426
Closed -$62.3K 1794
2024
Q4
$62.3K Sell
20,426
-52,654
-72% -$153K 0.01% 1331
2024
Q3
$186K Buy
73,080
+46,117
+171% +$140K 0.03% 765
2024
Q2
$87.9K Buy
26,963
+20,313
+305% +$89.2K 0.01% 1095
2024
Q1
$35.2K Buy
+6,650
New +$35.8K 0.01% 1459
2022
Q3
Sell
-20,732
Closed -$59K 1829
2022
Q2
$59K Sell
20,732
-25,074
-55% -$62.3K 0.04% 834
2022
Q1
$132K Buy
45,806
+4,285
+10% +$11.1K 0.07% 410
2021
Q4
$126K Buy
41,521
+37,818
+1,021% +$164K 0.06% 465
2021
Q3
$26K Sell
3,703
-38
-1% -$285 0.02% 898
2021
Q2
$34K Buy
+3,741
New +$37.9K 0.02% 837

Other funds holding PBYI

State of Wyoming's PBYI Position: Q2 2026 in Review

State of Wyoming reduced its Puma Biotechnology (PBYI) stake by 47% in Q2 2026, selling an estimated $263K and leaving 39,833 shares worth $323K. The position accounts for 0.03% of the portfolio, ranked #667.

State of Wyoming first reported a position in PBYI in Q2 2021 and has held it in 13 quarters since. The position peaked at $484K in Q1 2026. 160 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • State of Wyoming held 39,833 shares of Puma Biotechnology worth $323K as of Q2 2026.
  • State of Wyoming sold 35,975 Puma Biotechnology shares in Q2 2026, an estimated $263K.
  • Puma Biotechnology made up 0.03% of State of Wyoming's portfolio in Q2 2026, its #667 holding.
  • State of Wyoming first reported a position in Puma Biotechnology in Q2 2021 and has held it in 13 quarters since.
  • State of Wyoming's Puma Biotechnology position peaked at $484K in Q1 2026.
  • 160 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on State of Wyoming's 13F filing for Q2 2026, filed 6 Aug 2026.